Tracey L. McCain - Dec 7, 2021 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Role
EVP and Chief Legal Officer
Signature
/s/ Ariel Hurley, Attorney-in-Fact
Stock symbol
BPMC
Transactions as of
Dec 7, 2021
Transactions value $
-$344,690
Form type
4
Date filed
12/9/2021, 03:01 PM
Previous filing
Nov 17, 2021
Next filing
Mar 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BPMC Common Stock Options Exercise $142K +5K +14.95% $28.36 38.4K Dec 7, 2021 Direct F1, F2
transaction BPMC Common Stock Sale -$422K -4.33K -11.26% $97.46 34.1K Dec 7, 2021 Direct F1, F3
transaction BPMC Common Stock Sale -$55.1K -572 -1.68% $96.38 33.5K Dec 7, 2021 Direct F1, F4
transaction BPMC Common Stock Sale -$9.55K -100 -0.3% $95.54 33.4K Dec 7, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BPMC Stock Option (Right to Buy) Options Exercise $0 -5K -8.33% $0.00 55K Dec 7, 2021 Common Stock 5K $28.36 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effected pursuant to a trading plan adopted on February 22, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 Includes 167 shares that were previously acquired under the Issuer's employee stock purchase plan.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.97 to $97.91 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.87 to $96.73 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F5 This option was granted on October 3, 2016 and fully vested as of the date hereof.